TY - JOUR
T1 - Nanomedicine in non-small cell lung cancer
T2 - From conventional treatments to immunotherapy
AU - García-Fernández, Coral
AU - Fornaguera, Cristina
AU - Borrós, Salvador
N1 - Funding Information:
Acknowledgments: Support of Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya trough SGR 2017 1559 grant is acknowledged, as well as financial support from the Spanish CataluMniynaisttreoruiogdheSCGieRn2ci0a1,7 In15n5o9vgacraiónynt Uisnaicvkenrsoidwaldeedsg tehdr,oausgwh eglrlaanstf iRnTanI2c08ia1-0l 9su47p3p4o-rBt-fCro22m. .CtGh-eFSwpoanuilsdhl iMkei ntoisterio de Ciethnacniak, IIQnSn ofovrahceiór nPhyDU fenlilvoewrssihdiapSd..eBs. athckronuogwhlegdgraens tFRuTnIda2c0i1ó8C-0e9ll4e7x3 r4e-seBa-rCc2h2 g.rCan.Gt.F- Figwuroeuslwdelrikec eretoattehdaunskinIgQ S for her PhbDiorfeelnlodwers.hcoipm. .S.B. acknowledges Fundació Cellex research grant. Figures were created using biorender.com.
Funding Information:
Support of Agenda de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya trough SGR 2017 1559 grant is acknowledged, as well as financial support from the Spanish Ministerio de Ciencia, Innovacion y Universidades through grant RTI2018-094734-B-C22. C.G-F would like to thank IQS for her PhD fellowship. S.B. acknowledges Fundacio Cellex research grant. Figures were created using biorender.com.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/6
Y1 - 2020/6
N2 - Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.
AB - Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.
KW - Cancer vaccine
KW - Chemotherapy
KW - Immunotherapies
KW - Nanomedicine
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85086738465&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000549200800001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.3390/cancers12061609
DO - 10.3390/cancers12061609
M3 - Review
C2 - 32570729
AN - SCOPUS:85086738465
SN - 2072-6694
VL - 12
SP - 1
EP - 26
JO - Cancers
JF - Cancers
IS - 6
M1 - 1609
ER -
